On March 9, 2021 NanOlogy, LLC, a clinical-stage oncology company, reported that enrollment has been completed in its clinical trial of NanoDoce for bladder cancer (Press release, NanOlogy, MAR 9, 2021, View Source [SID1234576319]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Local bladder cancer at high risk for progression often requires removal of the bladder resulting in a severe lifelong quality of life issues. NanOlogy enrolled 36 bladder cancer patients in a Phase 1/2 two-arm trial evaluating direct injection/instillation of NanoDoce Suspension.

The first arm (n=19) included patients with high risk nonmuscle invasive bladder cancer. A high majority to date had a complete response at 3 months with 12 month data available in 2Q2021.

The second arm (n=17) included patients with muscle invasive bladder cancer. More than half have retained their bladder with no intervention at the initial study endpoint, now extended up to 12 months to test durability. These preliminary results will be updated and published once final.

On March 9, 2021 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, reported that it will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT) (Press release, MorphoSys, MAR 9, 2021, View Source [SID1234576318]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys’ Management team will host a conference call and webcast on March 16, 2021 at 2:00 pm CET (9:00 am EDT) to present results for the financial year 2020 and provide an outlook for 2021.

The conference call will start with a presentation by the Management team followed by a Q&A session. Presenters will be:

– Jean-Paul Kress, M.D., Chief Executive Officer

– Sung Lee, Chief Financial Officer

– Roland Wandeler, Ph.D., Chief Operating Officer

– Malte Peters, M.D., Chief Research & Development Officer

On March 9, 2021 Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Anker Lundemose, CEO, will present at Sachs’ 14th Annual European Life Sciences CEO Forum (Press release, Mission Therapeutics, MAR 9, 2021, View Source [SID1234576317]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anker Lundemose will present as part of a panel on 11 March at 15:10 CET discussing Mission’s Platform Technologies & Novel Therapeutics.

The Sachs Annual European Life Sciences CEO Forum, is a global big-pharma industry event that addresses the main challenges each year in investment, partnering and alliance management. The conference takes place over two days and features high-level speeches, panel discussions and spotlight showcases by leading industry corporates. It also brings together established public, private, emerging and seed companies, to offer innovative solutions, investment seeking and partnering opportunities with its global company showcase.

On March 9, 2021 Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, reported that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Thursday, March 18th, 2021, at 10:00 a.m. ET (Press release, Magenta Therapeutics, MAR 9, 2021, View Source [SID1234576316]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed on the Magenta Therapeutics website at View Source The webcast replay will be available for 90 days following the event.

On March 9, 2021 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the J.P. Morgan 2021 Virtual Industrials Conference webcast (Press release, Leidos, MAR 9, 2021, View Source [SID1234576315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roger Krone, Chief Executive Officer, will participate in a question and answer "fireside chat" on Tuesday, March 16, 2021 at 3:40 p.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.